SABCS: Imlunestrant Tied to Improved PFS for ER-Positive, HER2-Negative Breast Cancer With ESR1 Mutations
Imlunestrant leads to significantly longer progression-free survival among those with ESR1 mutations, but not in overall population
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.